NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount?
FDA milestone puts Neurocrine Biosciences in focus
The FDA’s acceptance of Neurocrine Biosciences (NBIX) Investigational New Drug application for NBI-1117567 clears the way for a Phase 2 trial in Alzheimer’s cognition and triggers a US$10 million payment to partner Nxera Pharma.
Despite the FDA milestone, Neurocrine Biosciences’ recent share price momentum has cooled, with the 30 day share price return down 14.79%, even as the year to date share price return is up 9.57% and the 5 year total...